Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Have a histologically or cytologically confirmed adenocarcinoma of the prostate Have metastatic disease documented by positive bone scan or by computed tomography or magnetic resonance imaging Have prostate cancer progression documented by prostate specific antigen according to Prostate Cancer Working Group 2 or radiographic progression according to modified RECIST (response evaluation criteria in solid tumors, v1.1) criteria Be asymptomatic from prostate cancer. A score of 0-1 on BPI-SF Question #3 (worst pain in last 24 hours) will be considered asymptomatic Be surgically or medically castrated, with testosterone levels of \<50 ng/dL (\<2.0 nmol/L). If the subject is being treated with luteinizing hormone releasing hormone (LHRH) agonists or antagonists (subjects who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Day 1, Cycle 1 and must be continued throughout the study.~Exclusion Criteria:~Has a history of pituitary or adrenal dysfunction Has an active infection or other medical condition that would contraindicate corticosteroid use Has any chronic medical condition requiring corticosteroid treatment or has received prior corticosteroid treatment for prostate cancer Has a pathological finding consistent with small cell carcinoma of the prostate Has a known brain metastasis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AA + prednisone 5 mg twice daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 5 mg twice daily
- AA + prednisone 5 mg once daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 5 mg once daily dose
- AA + prednisone 2.5 mg twice daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 2.5 mg twice daily
- AA + dexamethasone 0.5 mg once daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with dexamethasone 0.5 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).